Esperion Therapeutics (ESPR) Has Notable New Fan at the FDA and Should Be Bought on Weakness - Barclays

Esperion Therapeutics (ESPR) Adds Scott Braunstein, M.D., as Director

Esperion Therapeutics (NASDAQ: ESPR) announced the appointment of Scott Braunstein, M.D. as a Class III Director, with a term expiring at the 2016 annual meeting of stockholders.

"I'm very pleased to welcome Dr. Braunstein to the Esperion board," said Tim Mayleben, president and chief executive officer. "With an experience base which spans the healthcare sector -- first as a practicing physician and... More

Credit Suisse Defends Esperion Therapeutics (ESPR); Does Not See Impact from PCSK9 Panel

Credit Suisse is the latest firm to come out in defense of Esperion Therapeutics (NASDAQ: ESPR), which fell more than 20% today following the PCSK9 panel discussion yesterday, which some viewed as cautious for the label.

Analyst Jeremiah Shepard said they do not... More

Esperion Therapeutics (ESPR) Price Target Lowered to $50 at Chardan

Chardan Capital Markets maintained a Sell rating on Esperion Therapeutics (NASDAQ: ESPR) and lowered its price target to $50.00 (from $55.00). The change follows an FDA panel meeting and vote supporting approval of Regeneron's (NASDAQ: REGN) Praluent. Analyst Gbolahn Amusa... More

Pre-Open Stock Movers 06/10: (HCC) (CTIC) (HIMX) Higher; (BDBD) (ESPR) (FRAN) Lower (more...)

HCC Insurance Holdings, Inc. (NYSE: HCC) 36% HIGHER; Tokio Marine Holdings, Inc. (TMHD) and HCC Insurance Holdings, Inc. (HCC) (NYSE:... More

Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company Says

Needham & Company analyst Chad Messer reiterated a Buy rating and $130 price target on Esperion Therapeutics (NASDAQ: ESPR) following a read-through from Alirocumab AdComm, which they view as a net positive for ETC-1002.

Messer commented, "We walked away from the FDA advisory panel for... More

Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS Says

UBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR) saying they see a modest impact from the narrowed AdCom vote, discussion. Despite ultimately voting for approval, panellists at today's FDA AdCom on SNY/REGN's Praluent appeared... More

After-Hours Stock Movers 06/09: (REGN) (CTIC) (SIGM) HIGHER; (SALT) (RXDX) (HRTX) LOWER (more...)

Regeneron Pharmaceuticals (NASDAQ: REGN) INDICATED HIGHER (halted); Regeneron (NASDAQ: REGN) and Sanofi (NYSE: SNY) PCSK9 (proprotein convertase subtilisin/kexin type 9) drug, Praluent, wins FDA panel backing.

Scorpio Bulkers (NYSE:... More

Esperion (ESPR), Amgen (AMGN) Shares Weaken Post-Market After Praluent Gets FDA Backing

(Updated - June 9, 2015 5:49 PM EDT)

Esperion Therapeutics (NASDAQ: ESPR) shares declined after-hours Tuesday. Earlier an FDA panel voted to back Regeneron (NASDAQ: REGN) and Sanofi's (NYSE: SNY) PCSK9, Praluent. Shares of Amgen (NASDAQ: AMGN) are also trading down slightly.